icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria april 22-26
Back grey_arrow_rt.gif
 
 
 
SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of
Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with
AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment

 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
SJ Johnson1, H Parise1, S Virabhak1, tR Juday2, JC Samp2, SE Marx2, S Saab3 1Medicus Economics, Milton; 2Global Health Economics and Outcomes Research, AbbVie, Mettawa; 3Pfleger Liver Institute, Los Angeles, United States
 
EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)
 
EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) Ribavirin in the United States - (04/28/15)
 
EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif